FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808524407> ?p ?o ?g. }

• W2808524407 abstract "Background Uveitis is the most common ocular inflammatory disease. According to the classification, non-infectious uveitis 70% of the total, presenting a chronic course and with it, an increased risk of complications. The phased therapeutic approach in ophthalmology is well established and is based on the efficacy of synthetic and biological immunosuppressive therapy.1 However, we do not have evidence-based protocols that allow us to know how long to maintain them, or when to interrupt them. Objectives The main objective is to evaluate the free time without ocular inflammatory activity after the withdrawal of the synthetic and/or biological immunosuppressive treatment in patients with non-infectious uveitis. As secondary objectives are collected the epidemiological and clinical characteristics, the distribution of the different immunosuppressive drugs employed and analysed the cases of recurrence after the interruption of treatment, and the need of reintroduction. Methods A retrospective cohort multicenter study was conducted in patients with a diagnosis of non-infectious uveitis followed in a multidisciplinary unit, that after two or more years of ocular and extraocular inactivity, the inmunossuppresive treatment was suspended. It was defined inactive uveitis as cell Tyndall 0 in anterior and vitreous chamber, as well as the absence of other signs of active inflammation (retinal infiltrates, choroid and vasculitis and/or papillitis with angiographic leakage). Demographic characteristics, anatomical location and laterality of the uveitis, visual acuity at the beginning and end of the study and the drugs used were recorded. Results We analysed 48 patients with an average age at the onset of immunosuppressive treatment of 39.3 years (±16 years). 85.4% of the uveitis were bilateral. The main diagnoses are described in table 1. In 56.3% of cases a single immunosuppressant was used. Cyclosporine was the most employed (72.9%) and methotrexate was the most used in monotherapy (83.3%). 83% of patients received corticosteroids and 12% treatment with Infliximab. The mean duration of immunosuppressive treatment was 6.9 years (±5, 7anos). The percentage of total and ocular recurrence was 37.5% and 31.25% respectively. The mean duration of follow-up after treatment suspension was 4.3 years (±4.5 years), being more than 1 year in 77.1% of patients. We found that 75% of patients remained free of recurrence at least 27 months. The administration of two or more immunosuppresive drugs proved to be a risk factor for recurrence (p=0,048) and reintroduction of treatment after it (p=0,008), which was performed in 39% of the ocular recurrences. Visual acuity did not suffer variation in 78.6% of recurrences and 80.3% of those that did not recur. Conclusions In our cohort, patients with no ocular inflammatory activity for at least two years could benefit from the suspension of immunosuppressive treatment without a visual risk. The use of one or more immunosuppressive drugs has been identified as a risk factor for recurrence. Reference [1] Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets2013;12(1):38–45. Disclosure of Interest None declared" @default.
• W2808524407 created "2018-06-21" @default.
• W2808524407 creator A5000127704 @default.
• W2808524407 creator A5022519054 @default.
• W2808524407 creator A5052945599 @default.
• W2808524407 creator A5053341568 @default.
• W2808524407 creator A5056126524 @default.
• W2808524407 creator A5072596424 @default.
• W2808524407 creator A5080382718 @default.
• W2808524407 creator A5086878287 @default.
• W2808524407 date "2018-06-01" @default.
• W2808524407 modified "2023-10-06" @default.
• W2808524407 title "SAT0595 Analysis of recurrences after suspension of immunosuppressive treatment in non-infectious uveitis" @default.
• W2808524407 doi "https://doi.org/10.1136/annrheumdis-2018-eular.5105" @default.
• W2808524407 hasPublicationYear "2018" @default.
• W2808524407 type Work @default.
• W2808524407 sameAs 2808524407 @default.
• W2808524407 citedByCount "0" @default.
• W2808524407 crossrefType "proceedings-article" @default.
• W2808524407 hasAuthorship W2808524407A5000127704 @default.
• W2808524407 hasAuthorship W2808524407A5022519054 @default.
• W2808524407 hasAuthorship W2808524407A5052945599 @default.
• W2808524407 hasAuthorship W2808524407A5053341568 @default.
• W2808524407 hasAuthorship W2808524407A5056126524 @default.
• W2808524407 hasAuthorship W2808524407A5072596424 @default.
• W2808524407 hasAuthorship W2808524407A5080382718 @default.
• W2808524407 hasAuthorship W2808524407A5086878287 @default.
• W2808524407 hasBestOaLocation W28085244071 @default.
• W2808524407 hasConcept C118487528 @default.
• W2808524407 hasConcept C120665830 @default.
• W2808524407 hasConcept C121332964 @default.
• W2808524407 hasConcept C126322002 @default.
• W2808524407 hasConcept C141071460 @default.
• W2808524407 hasConcept C167135981 @default.
• W2808524407 hasConcept C2776015282 @default.
• W2808524407 hasConcept C2776194053 @default.
• W2808524407 hasConcept C2776694393 @default.
• W2808524407 hasConcept C2777093970 @default.
• W2808524407 hasConcept C2778328719 @default.
• W2808524407 hasConcept C2778720950 @default.
• W2808524407 hasConcept C2779134260 @default.
• W2808524407 hasConcept C71924100 @default.
• W2808524407 hasConceptScore W2808524407C118487528 @default.
• W2808524407 hasConceptScore W2808524407C120665830 @default.
• W2808524407 hasConceptScore W2808524407C121332964 @default.
• W2808524407 hasConceptScore W2808524407C126322002 @default.
• W2808524407 hasConceptScore W2808524407C141071460 @default.
• W2808524407 hasConceptScore W2808524407C167135981 @default.
• W2808524407 hasConceptScore W2808524407C2776015282 @default.
• W2808524407 hasConceptScore W2808524407C2776194053 @default.
• W2808524407 hasConceptScore W2808524407C2776694393 @default.
• W2808524407 hasConceptScore W2808524407C2777093970 @default.
• W2808524407 hasConceptScore W2808524407C2778328719 @default.
• W2808524407 hasConceptScore W2808524407C2778720950 @default.
• W2808524407 hasConceptScore W2808524407C2779134260 @default.
• W2808524407 hasConceptScore W2808524407C71924100 @default.
• W2808524407 hasLocation W28085244071 @default.
• W2808524407 hasOpenAccess W2808524407 @default.
• W2808524407 hasPrimaryLocation W28085244071 @default.
• W2808524407 hasRelatedWork W1968779223 @default.
• W2808524407 hasRelatedWork W1988413772 @default.
• W2808524407 hasRelatedWork W2055800764 @default.
• W2808524407 hasRelatedWork W2055864508 @default.
• W2808524407 hasRelatedWork W2097741071 @default.
• W2808524407 hasRelatedWork W2127133939 @default.
• W2808524407 hasRelatedWork W2133321705 @default.
• W2808524407 hasRelatedWork W2161892030 @default.
• W2808524407 hasRelatedWork W2182816677 @default.
• W2808524407 hasRelatedWork W2319411450 @default.
• W2808524407 hasRelatedWork W2330255297 @default.
• W2808524407 hasRelatedWork W2332852477 @default.
• W2808524407 hasRelatedWork W2562385411 @default.
• W2808524407 hasRelatedWork W2596848781 @default.
• W2808524407 hasRelatedWork W2608839610 @default.
• W2808524407 hasRelatedWork W2767182178 @default.
• W2808524407 hasRelatedWork W2788531276 @default.
• W2808524407 hasRelatedWork W2949924460 @default.
• W2808524407 hasRelatedWork W3032768597 @default.
• W2808524407 hasRelatedWork W3081315736 @default.
• W2808524407 isParatext "false" @default.
• W2808524407 isRetracted "false" @default.
• W2808524407 magId "2808524407" @default.
• W2808524407 workType "article" @default.